360 results match your criteria Controversies in Prostate Cancer

Editorial comment on Evolution, controversies and the future of prostate cancer grading.

Toyonori Tsuzuki

Pathol Int 2019 02 9;69(2):67. Epub 2019 Feb 9.

Department of Surgical Pathology, Aichi Medical University Hospital, 1-1 Yazakokarimata, Nagakute, 480-1195, Japan.

View Article and Full-Text PDF
February 2019

Evolution, controversies and the future of prostate cancer grading.

Pathol Int 2019 Feb 29;69(2):55-66. Epub 2019 Jan 29.

Aquesta Uropathology and University of Queensland, Brisbane, Queensland, Australia.

Histological grading of prostate cancer is one of the most important tissue-based parameters for prediction of outcome and treatment response. Gleason grading remains the foundation of prostate cancer grading, but has undergone a series of changes in the past 30 years, often initiated by consensus conference decisions. This review summarizes the most important modifications that were introduced by the 2005 and 2014 International Society of Urological Pathology (ISUP) revisions of Gleason grading and discusses the impact that these have had on current grading practices. Read More

View Article and Full-Text PDF
February 2019

Controversies in MR targeted biopsy: alone or combined, cognitive versus software-based fusion, transrectal versus transperineal approach?

World J Urol 2019 Feb 4;37(2):277-287. Epub 2019 Jan 4.

Department of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.

Purpose: To review the evidence addressing current controversies around prostate biopsy. Specific questions explored were (1) mpMRI targeted (TgBx) alone versus combined with systematic (SBx) biopsy; (2) cognitive versus software-based targeted biopsy; (3) transrectal or transperineal route (TP).

Methods: We performed a literature search of peer-reviewed English language articles using PubMed and the words "prostate" AND "biopsy". Read More

View Article and Full-Text PDF
February 2019

Current controversies on the role of lymphadenectomy for prostate cancer.

Urol Oncol 2019 03 19;37(3):219-226. Epub 2018 Dec 19.

The Smith Institute for Urology, Zucker School of Medicine Hofstra/Northwell, New Hyde Park, NY. Electronic address:

Lymph node dissection is part of the standard treatment protocol for various cancers, but its role in prostate cancer has been debatable for some time. Pelvic lymphadenectomy has been shown to better help stage prostate cancer patients, but has yet to be definitively proven to be of any benefit for survival. Various templates for lymph node dissections exist, and though some national guidelines have endorsed an extended pelvic node dissection, the choice of template is still controversial. Read More

View Article and Full-Text PDF

Laparoscopic transperitoneal inguinal hernioplasty (TAPP) after radical open retropubic prostatectomy: special features and clinical outcomes.

W K J Peitsch

Hernia 2019 04 7;23(2):281-286. Epub 2018 Nov 7.

Department of General, Visceral, Vascular and Trauma Surgery, St. Josef Hospital Werden, University Medicine Essen, Propsteistrasse 2, 45239, Essen, Germany.

Purpose Laparoscopic transperitoneal endoscopic (TAPP) and totally extraperitoneal (TEP) hernia repair have been well established in primary and recurrent inguinal hernias [1]. Only few studies [2-5] evaluate the surgical outcome of patients with inguinal hernias after radical prostatectomy, using the TAPP or TEP procedure. But controversies remain including its feasibility, safety and recurrence rate. Read More

View Article and Full-Text PDF

[Prostate cancer screening: controversies and suggested solutions].

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2018 Dec;61(12):1544-1550

Klinik für Urologie, Universitätsklinikum Düsseldorf, Moorenstr. 5, 40225, Düsseldorf, Deutschland.

Prostate cancer is the most common cancer among men in industrialized countries. The annual incidence rate in Germany is about 60,000. Every year, 13,000 men die of this disease. Read More

View Article and Full-Text PDF
December 2018

Multiparametric MRI and MRI/TRUS Fusion Guided Biopsy for the Diagnosis of Prostate Cancer.

Adv Exp Med Biol 2018;1096:87-98

Department of Urology, University Hospital Heidelberg, Heidelberg, Germany.

Purpose of this chapter To demonstrate the timing, benefits, limitations and current controversies of multiparametric magnet resonance imaging (mpMRI) combined with fusion guided biopsy and consider how additional incorporation of multivariable risk stratification might further improve prostate cancer (PC) diagnosis. Recent findings MpMRI has been shown to add important information to the diagnostic pathway for prostate cancer. Fusion biopsy has also shown advantages in comparison to standard practice for biopsy-naïve men and men with previous biopsy in large prospective studies providing level 1b evidence. Read More

View Article and Full-Text PDF

Prostate Cancer Pathology: Recent Updates and Controversies.

Jennifer K Sehn

Mo Med 2018 Mar-Apr;115(2):151-155

Jennifer K. Sehn, MD, is Assistant Professor, Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri.

Prostate cancer is common, and recent efforts in clinical management have focused on identifying patients who could be candidates from less aggressive management or who could benefit from more aggressive therapy. As prostate cancer histology, especially Gleason score, plays a critical role in predicting patient outcomes, attempts have been made to refine histologic classification and reporting in prostate cancer to facilitate patient risk stratification. This review discusses recent updates in prostate cancer grading and reporting. Read More

View Article and Full-Text PDF

Novel Diagnostic Biomarkers of Prostate Cancer: An Update.

Curr Med Chem 2019 ;26(6):1045-1058

Department of Urology, "Regina Elena" National Cancer Institute, Rome, Italy.

Objective: In recent years, several biomarkers alternative to standard prostate specific antigen (PSA) for prostate cancer (PCa) diagnosis have become available. The aim of this systematic review is to assess the current knowledge about alternative serum and urinary biomarkers for the diagnosis of PCa.

Material And Methods: A research was conducted in Medline, restricted to English language articles published between December 2014 and June 2018 with the aim to update previously published series on PCa biomarkers. Read More

View Article and Full-Text PDF

Prostate cancer treatment by the latest focal HIFU device with MRI/TRUS-fusion control biopsies: A prospective evaluation.

Urol Oncol 2018 09 6;36(9):401.e1-401.e9. Epub 2018 Aug 6.

Department of Urology, University Medical Center Mannheim, Medical Faculty Mannheim, University of Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany.

Objectives: Magnetic resonance imaging/transrectal ultrasound (MRI/TRUS) fusion-guided focal high intensity focused ultrasound (HIFU) therapy of the prostate has recently been developed as a selective HIFU-therapy technique to enable targeted ablation of prostate cancer. Here we report a series of patients treated with focal HIFU therapy, discuss its potential pitfalls, and address controversies concerning the indications.

Materials And Methods: This single-center prospective study reports outcomes of patients treated from September 2014 to March 2016. Read More

View Article and Full-Text PDF
September 2018

Contemporary role of postoperative radiotherapy for prostate cancer.

Transl Androl Urol 2018 Jun;7(3):399-413

Department of Radiation Oncology, University of Miami Miller School of Medicine, Miami, FL, USA.

While radical prostatectomy (RP) has provided long-term disease control for the majority of patients with localized prostate cancer (CaP), nearly 30% of all surgical patients have disease progression. For high-risk patients, more than half of men experience disease recurrence within 10 years. Postoperative radiotherapy is the only known potentially curative treatment for a large number of patients following prostatectomy. Read More

View Article and Full-Text PDF

Treatment of hormone-naïve metastatic prostate cancer.

Curr Opin Support Palliat Care 2018 09;12(3):334-338

Département De Médecine Oncologique, Institut Gustave Roussy, Université Paris-Saclay, Paris, France.

Purpose Of Review: Until 2015, androgen deprivation therapy (ADT) alone was the standard-of-care for metastatic hormone-naïve prostate cancer (mHNPC). In the last decade, important landmark therapeutic advances occurred in the management of these patients permitting improvement of their survival.

Recent Findings: At least two prospective randomized trials proved upfront docetaxel (DOC) + ADT benefit consequently providing strong evidence for guidelines modifications. Read More

View Article and Full-Text PDF
September 2018

The role of CD133 in cancer: a concise review.

Clin Transl Med 2018 Jul 9;7(1):18. Epub 2018 Jul 9.

Department of Pharmacology, University of Minnesota Medical School, Nils Hasselmo Hall 3-104, 312 Church St. SE, Minneapolis, MN, 55455, USA.

Despite the abundant ongoing research efforts, cancer remains one of the most challenging diseases to treat globally. Due to the heterogenous nature of cancer, one of the major clinical challenges in therapeutic development is the cancer's ability to develop resistance. It has been hypothesized that cancer stem cells are the cause for this resistance, and targeting them will lead to tumor regression. Read More

View Article and Full-Text PDF

Simplified Prostate Imaging Reporting and Data System for Biparametric Prostate MRI: A Proposal.

AJR Am J Roentgenol 2018 08 12;211(2):379-382. Epub 2018 Jun 12.

4 Department of Urology, Clinica Castelli, Bergamo, Italy.

Objective: We describe our institutional experience using a simplified Prostate Imaging Reporting and Data System (PI-RADS) based on biparametric prostate MRI. We discuss two important controversies: the use of gadolinium-based contrast agents and the management of PI-RADS category 3 lesions.

Conclusion: Our simplified PI-RADS identifies four categories and suggests management strategies for each. Read More

View Article and Full-Text PDF

The History of Testosterone and the Evolution of its Therapeutic Potential.

Sex Med Rev 2020 Apr 13;8(2):286-296. Epub 2018 Apr 13.

Boston University School of Medicine, Boston, MA, USA.

Introduction: Testosterone therapy has been controversial since its synthesis in the 1930s to the present day. Testosterone's history provides depth and context for current controversies.

Aim: To review the history of testosterone therapy from its initial synthesis in the 1930s to the modern day. Read More

View Article and Full-Text PDF

Standards, innovations, and controversies in urologic imaging.

World J Urol 2018 05;36(5):685-686

Department of Urology, Diakonissenkrankenhaus Flensburg, University Teaching Hospital of the Christian-Albrechts-Universität Kiel, Flensburg, Germany.

View Article and Full-Text PDF

Current Progress and Controversies in Prostate Cancer Management.

Chin Med J (Engl) 2017 Dec;130(24):2991-2995

Department of Urology, Chinese Academy of Medical Sciences, Peking Union Medical College Hospital, Beijing 100730, China.

Objective: The optimal management strategy for prostate cancer (PCa) remains controversial. We performed a systemic review of current progress and controversies regarding the diagnosis and treatment of PCa.

Data Sources: We searched PubMed for recently published articles up to July 2017 using the following key words: "prostate cancer," "progress," "controversy," "immunotherapy," and "prevention. Read More

View Article and Full-Text PDF
December 2017

Editorial: Controversies and Perspectives in the Use of Postoperative Radiotherapy for Prostate Cancer.

Front Oncol 2017 23;7:275. Epub 2017 Nov 23.

Department of Radiation Oncology, Institut de Cancérologie de l'Ouest, Nantes, France.

View Article and Full-Text PDF
November 2017

Men's perspectives of prostate cancer screening: A systematic review of qualitative studies.

PLoS One 2017 28;12(11):e0188258. Epub 2017 Nov 28.

Sydney School of Public Health, The University of Sydney, Sydney, Australia.

Background: Prostate cancer is the most commonly diagnosed non-skin cancer in men. Screening for prostate cancer is widely accepted; however concerns regarding the harms outweighing the benefits of screening exist. Although patient's play a pivotal role in the decision making process, men may not be aware of the controversies regarding prostate cancer screening. Read More

View Article and Full-Text PDF
December 2017

Radical Prostatectomy for Patients With Oligometastatic Prostate Cancer.

Oncology (Williston Park) 2017 11;31(11):794-802

Cancer progresses in a stepwise fashion. Oligometastatic cancer is an intermediate stage of tumor spread between localized disease and disseminated metastases. Oligometastatic prostate cancer is defined as up to five extrapelvic lesions on conventional imaging. Read More

View Article and Full-Text PDF
November 2017

Prognostic role of tumour-associated macrophages and macrophage scavenger receptor 1 in prostate cancer: a systematic review and meta-analysis.

Oncotarget 2017 Oct 27;8(47):83261-83269. Epub 2017 Jun 27.

MRC Centre for Reproductive Health, Queen's Medical Research Institute, Edinburgh EH16 4TJ, United Kingdom.

Recent studies suggested that the tumour associated macrophages may be associated with prostate cancer outcome. A meta-analysis was performed to evaluate the prognostic value of tumor associated macrophages and macrophage scavenger receptor 1, marker for a subset of macrophages, by pooled hazard ratio and 95% confidence intervals from qualified studies following a systemic search. The results indicate that higher infiltration of tumor associated macrophages predicts poor overall survival (HR=1. Read More

View Article and Full-Text PDF
October 2017

Controversies in PSA screening.

Jack O'Sullivan

Evid Based Med 2017 12 9;22(6):198. Epub 2017 Nov 9.

View Article and Full-Text PDF
December 2017

Prostate cancer prevention with 5-alpha reductase inhibitors: concepts and controversies.

Curr Opin Urol 2018 Jan;28(1):42-45

CHRISTUS Santa Rosa Medical Center Hospital, CHRISTUS Research Institute, San Antonio, Texas, USA.

Purpose Of Review: We review the concepts surrounding prostate cancer prevention strategies with 5-alpha reductase inhibitors (5-ARIs) and the controversies associated with their use.

Recent Findings: Updated data have shown no increased risk of death from the diagnosis of higher risk cancer; however, 5-ARIs remain controversial and not approved for prostate cancer prevention.

Summary: The main theme of the review identifies the success of reducing insignificant prostate cancer and the controversy with the increased association of higher risk prostate cancer by approximately 20%. Read More

View Article and Full-Text PDF
January 2018

Multiparametric MRI fusion-guided biopsy for the diagnosis of prostate cancer.

Curr Opin Urol 2018 03;28(2):172-177

Department of Urology, University Hospital Heidelberg, Heidelberg, Germany.

Purpose Of Review: To discuss the timing, benefits, limitations and current controversies of multiparametric magnet resonance imaging (mpMRI) combined with fusion-guided biopsy and consider how additional incorporation of multivariable risk stratification might further improve prostate cancer diagnosis.

Recent Findings: MpMRI has been proven advantageous over standard practice for biopsy-naïve men and men with previous biopsy in large prospective studies providing level 1b evidence. Upfront multivariable risk stratification followed by or combined with mpMRI further improves diagnostic accuracy. Read More

View Article and Full-Text PDF

Concomitant bladder cancer and prostate cancer: challenges and controversies.

Nat Rev Urol 2017 Oct 16;14(10):620-629. Epub 2017 Aug 16.

Institute of Pathological Anatomy and Histopathology, Polytechnic University of the Marche Region (Ancona), School of Medicine, United Hospitals, Via Conca 71, 60126 Torrette, Ancona, Italy.

Radical cystoprostatectomy (RCP) followed by bilateral pelvic lymphadenectomy and urinary diversion remains the gold-standard therapy for men with localized muscle-invasive bladder cancer (MIBC). Prostate cancer might be incidentally detected at the time of RCP with a reported prevalence of 24-51%. Typically, these patients are considered to have clinically insignificant disease, but data from emerging series challenge this assumption and suggest that some of these tumours might be aggressive, or somehow increase the aggressiveness of the associated MIBC, and can negatively influence the patient's overall survival outcomes. Read More

View Article and Full-Text PDF
October 2017

Angiomotin Family Members: Oncogenes or Tumor Suppressors?

Int J Biol Sci 2017 1;13(6):772-781. Epub 2017 Jun 1.

Department of Oncology, the First Affiliated Hospital of Xian Jiaotong University, Xi'an, Shaanxi Province ,710061, P.R. China.

Angiomotin (Amot) family contains three members: Amot (p80 and p130 isoforms), Amot-like protein 1 (Amotl1), and Amot-like protein 2 (Amotl2). Amot proteins play an important role in tube formation and migration of endothelial cells and the regulation of tight junctions, polarity, and epithelial-mesenchymal transition in epithelial cells. Moreover, these proteins regulate the proliferation and migration of cancer cells. Read More

View Article and Full-Text PDF

Taking the first steps in establishing recommendations for testosterone monitoring in men with prostate cancer on androgen-deprivation therapy.

Alvaro Morales

Can Urol Assoc J 2017 Jun;11(6):210-211

Department of Urology, Queen's University, Kingston, ON, Canada.

The paper by Shayegan et al in this issue of represents an important initial step in establishing recommendations for hormonal monitoring in men with prostate cancer on androgen-deprivation therapy (ADT). As with most subjects related to the actions of testosterone, the survey adds to the controversies, but also opens the opportunity to explore several of the concerns relevant to the hormonal management of prostate cancer. Read More

View Article and Full-Text PDF

Delineation of the Prostate Bed: The "Invisible Target" Is Still an Issue?

Front Oncol 2017 31;7:108. Epub 2017 May 31.

Department of Radiotherapy, Centre Léon Bérard, Lyon, France.

For pathological high-risk prostate cancer, adjuvant irradiation has shown a survival benefit. Phase III studies have highlighted that half men would face biochemical relapse and would be candidate for radiotherapy at adjuvant or salvage times. Despite at least four published international contouring guidelines from different collaborative groups, discrepancies remain for volumes, delineation, and margins to be considered in order to optimize radiotherapy planning. Read More

View Article and Full-Text PDF

The use of Hormonal Therapy to Augment Radiation Therapy in Prostate Cancer: An Update.

Curr Urol Rep 2017 Jul;18(7):50

Department of Radiation and Cellular Oncology, University of Chicago, 5758 South Maryland Avenue MC 9006, Chicago, IL, 60637, USA.

Purpose Of Review: Androgen deprivation therapy (ADT) is an important adjunctive therapy to external beam radiation therapy (RT) for the definitive management of prostate cancer. The role of ADT is well-established for locally advanced or high-risk disease in conjunction with standard doses of RT, but less defined for intermediate-risk disease or with dose-escalated RT. The goal of this review is to summarize evidence evaluating the combination of ADT/RT, focusing on recent trials and current controversies as they pertain to the practicing clinician. Read More

View Article and Full-Text PDF

Controversies and consensus in the innovation access for cancer therapy in the European countries: on the subject of metastatic prostate cancer.

S Oudard F Courbon

Ann Oncol 2017 02;28(2):421-426

Department of Medical Imaging, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France.

Innovative cancer therapies and advances in drug development have created new hopes for patients and health providers. The purpose of this article was to evaluate the discrepancies in the assessment of the magnitude of benefit of four new drugs (abiraterone acetate, enzalutamide, cabazitaxel, radium-223 dichloride) for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The comparison was done among three European countries (UK, Germany and France) and Canada, according to the statement of each country and to the European Society of Medical Oncology (ESMO) Magnitude of Clinical Benefit Scale. Read More

View Article and Full-Text PDF
February 2017